GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Short Interest

Arch Biopartners (TSXV:ARCH) Short Interest


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Arch Biopartners's Short Interest

For the Biotechnology subindustry, Arch Biopartners's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Short Interest distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Short Interest falls into.


;
;

Arch Biopartners Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Short Interest
Comparable Companies
TSX:MSCL TSX:MDNA XCNQ:GLAB TSX:ONC TSXV:COV XCNQ:ONCO TSXV:MIR TSX:SVA TSX:TH TSXV:NRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ACHFF:USA
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Website
https://www.archbiopartners.com
Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.